7 results
10-K
2021 FY
IKNA
Ikena Oncology, Inc.
17 Mar 22
Annual report
6:31am
develop resistance to this treatment, which poses a significant challenge due to the scarcity of post-osimertinib pharmacological options available
424B4
IKNA
Ikena Oncology, Inc.
26 Mar 21
Prospectus supplement with pricing info
5:04pm
by osimertinib, patients often develop resistance to this treatment, which poses a significant challenge due to the scarcity of post-osimertinib pharmacological
S-1/A
IKNA
Ikena Oncology, Inc.
22 Mar 21
IPO registration (amended)
8:51am
to this treatment, which poses a significant challenge due to the scarcity of post-osimertinib pharmacological options available to date. Early use
S-1
IKNA
Ikena Oncology, Inc.
5 Mar 21
IPO registration
2:59pm
by osimertinib, patients often develop resistance to this treatment, which poses a significant challenge due to the scarcity of post-osimertinib
DRS/A
h0wxpn q0l4xap3udo
11 Feb 21
Draft registration statement (amended)
12:00am
DRS
xy31ega
8 Jan 21
Draft registration statement
12:00am
- Prev
- 1
- Next